Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as (OMP-18R5)
Vantictumab combined with paclitaxel · 1 trial · 1 indication
The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with paclitaxel
| Arm | Type | Description |
|---|---|---|
| Vantictumab combined with paclitaxel | EXPERIMENTAL | Drug: vantictumab combined with paclitaxel - administered intravenously |
| Name | Type | Description |
|---|---|---|
| Vantictumab combined with paclitaxel | DRUG | Vantictumab combined with paclitaxel will be administered IV. |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease o Patients with breast cancer overexpressing HER2 are not eligible. * Availability of tumor tissue, either archival FFPE or obt...
Top 20 of 87 competitors
Vantictumab combined with paclitaxel is an investigational cancer treatment pairing a monoclonal antibody with the chemotherapy drug paclitaxel. It was studied in locally recurrent or metastatic breast cancer. The combination is not approved and remains in clinical development, with the Phase 1 trial completed.
Vantictumab combined with paclitaxel was studied for the treatment of locally recurrent or metastatic breast cancer in adult women. The Phase 1 trial enrolled 37 patients with metastatic breast cancer in the United States. It is an investigational regimen and is not an approved therapy.
Vantictumab targets the Frizzled receptors FZD1, FZD2, FZD5, FZD7, and FZD8. It acts as an antagonist of these receptors, which are part of the Wnt signaling pathway. By blocking these FZD receptors, vantictumab is designed to inhibit Wnt pathway activity in cancer cells.
Mereo BioPharma Group plc, which trades under the ticker MREO, is the developer of vantictumab combined with paclitaxel. The company is advancing the monoclonal antibody in oncology, with the combination studied in metastatic breast cancer.
Vantictumab combined with paclitaxel is in Phase 1 development. The single Phase 1 trial, NCT01973309, has been completed. The regimen is investigational and has not been approved by the FDA for any indication.
Vantictumab combined with paclitaxel was evaluated in one clinical trial, NCT01973309, titled A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer. The Phase 1 trial enrolled 37 patients in the United States and is completed.